Literature DB >> 22669395

[Efficacy of adjuvant zoledronic acid in breast cancer therapy remains unclear].

M-L Sautter-Bihl1.   

Abstract

Entities:  

Year:  2012        PMID： 22669395     DOI： 10.1007/s00066-012-0148-6

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  4 in total

1.  Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.

Authors:  Michael Gnant; Brigitte Mlineritsch; Herbert Stoeger; Gero Luschin-Ebengreuth; Dietmar Heck; Christian Menzel; Raimund Jakesz; Michael Seifert; Michael Hubalek; Gunda Pristauz; Thomas Bauernhofer; Holger Eidtmann; Wolfgang Eiermann; Guenther Steger; Werner Kwasny; Peter Dubsky; Gerhard Hochreiner; Ernst-Pius Forsthuber; Christian Fesl; Richard Greil
Journal:  Lancet Oncol       Date:  2011-06-05       Impact factor: 41.316

Review 2.  The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials.

Authors:  Tingting Yan; Wenjin Yin; Qiong Zhou; Liheng Zhou; Yiwei Jiang; Yueyao Du; Zhimin Shao; Jinsong Lu
Journal:  Eur J Cancer       Date:  2011-11-17       Impact factor: 9.162

Review 3.  The impact of age on outcome in early-stage breast cancer.

Authors:  Beth M Beadle; Wendy A Woodward; Thomas A Buchholz
Journal:  Semin Radiat Oncol       Date:  2011-01       Impact factor: 5.934

4.  Breast-cancer adjuvant therapy with zoledronic acid.

Authors:  Robert E Coleman; Helen Marshall; David Cameron; David Dodwell; Roger Burkinshaw; Maccon Keane; Miguel Gil; Stephen J Houston; Robert J Grieve; Peter J Barrett-Lee; Diana Ritchie; Julia Pugh; Claire Gaunt; Una Rea; Jennifer Peterson; Claire Davies; Victoria Hiley; Walter Gregory; Richard Bell
Journal:  N Engl J Med       Date:  2011-09-25       Impact factor: 91.245
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.